Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Neurogene Inc.NLTX · Entity 5160 | Senior Vice President | August 02, 2022 | August 04, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Neurogene Inc.
Report date August 02, 2022 · Filed August 04, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.99 · Expires 2032-08-01 | Direct | 150,000 |
Reported balance
After 2022-08-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-08-02 · Grant · Acquired 150,000 · Balance 150,000 F1: The option vests as to 1/4 of the total shares on August 2, 2023, and then 1/48 of the total shares will vest monthly thereafter, subject to the Reporting Person's provision of service to the Issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests as to 1/4 of the total shares on August 2, 2023, and then 1/48 of the total shares will vest monthly thereafter, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 02, 2022 Filed Aug 4, 2022 16:43 UTC | Neurogene Inc. NLTX · Entity 5160 | GrantStock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $0.99 | $0.00 |
DisclosureSEC source: 0001209191-22-044435 · doc4.xml · derivative · entry 1 Walkey Carl · CIK 0001843189 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2032-08-01 F1 · derivative.exercise_date: The option vests as to 1/4 of the total shares on August 2, 2023, and then 1/48 of the total shares will vest monthly thereafter, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| February 01, 2022 Filed Feb 2, 2022 16:42 UTC | Neurogene Inc. NLTX · Entity 5160 | GrantRestricted Stock Units · Derivative | 55,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-006398 · doc4.xml · derivative · entry 1 Walkey Carl · CIK 0001843189 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F2 · derivative.exercise_date: The RSUs will vest as to 1/2 of the total number of shares underlying the award on each of February 1, 2023 and February 1, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F3 · derivative.expiration_date: The RSUs do not expire; these securities either vest and settle or are canceled prior to the vesting date. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 16:29 UTC | Neurogene Inc. NLTX · Entity 5160 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $6.80 | $0.00 |
DisclosureSEC source: 0001209191-21-049941 · doc4.xml · derivative · entry 1 Walkey Carl · CIK 0001843189 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2031-08-03 F1 · derivative.exercise_date: The option vests as to 1/4 of the total shares on August 3, 2022, and then 1/48 of the total shares will vest monthly thereafter, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| June 16, 2021 Filed Jun 17, 2021 21:46 UTC | Neurogene Inc. NLTX · Entity 5160 | SaleCommon Stock | 600 | $10.19 | $6,114.00 |
DisclosureSEC source: 0001209191-21-041814 · doc4.xml · nonDerivative · entry 1 Walkey Carl · CIK 0001843189 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,352,489 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document |
| June 09, 2021 Filed Jun 11, 2021 16:13 UTC | Neurogene Inc. NLTX · Entity 5160 | SaleCommon Stock | 650 | $10.82 | $7,035.99 |
DisclosureSEC source: 0001209191-21-039819 · doc4.xml · nonDerivative · entry 1 Walkey Carl · CIK 0001843189 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,353,089 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $10.81 and the highest price at which shares were sold was $11.00. The reporting person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. Read SEC document |
| June 08, 2021 Filed Jun 9, 2021 17:22 UTC | Neurogene Inc. NLTX · Entity 5160 | SaleCommon Stock | 600 | $11.00 | $6,600.00 |
DisclosureSEC source: 0001209191-21-039223 · doc4.xml · nonDerivative · entry 1 Walkey Carl · CIK 0001843189 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,353,739 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document |
| June 04, 2021 Filed Jun 7, 2021 17:07 UTC | Neurogene Inc. NLTX · Entity 5160 | SaleCommon Stock | 600 | $10.00 | $6,000.00 |
DisclosureSEC source: 0001209191-21-038696 · doc4.xml · nonDerivative · entry 1 Walkey Carl · CIK 0001843189 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,354,339 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document |
| May 26, 2021 Filed May 26, 2021 19:37 UTC | Neurogene Inc. NLTX · Entity 5160 | SaleCommon Stock | 600 | $10.00 | $6,000.00 |
DisclosureSEC source: 0001209191-21-036057 · doc4.xml · nonDerivative · entry 1 Walkey Carl · CIK 0001843189 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,354,939 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document |
| May 19, 2021 Filed May 21, 2021 17:24 UTC | Neurogene Inc. NLTX · Entity 5160 | SaleCommon Stock | 600 | $10.63 | $6,378.00 |
DisclosureSEC source: 0001209191-21-035020 · doc4.xml · nonDerivative · entry 1 Walkey Carl · CIK 0001843189 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,355,539 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2 · balance_after: Includes 1,377 shares of Common Stock acquired on May 14, 2021 pursuant to the Issuer's employee stock purchase plan. Read SEC document |
| May 12, 2021 Filed May 12, 2021 20:53 UTC | Neurogene Inc. NLTX · Entity 5160 | SaleCommon Stock | 1,200 | $11.09 | $13,308.00 |
DisclosureSEC source: 0001209191-21-032244 · doc4.xml · nonDerivative · entry 1 Walkey Carl · CIK 0001843189 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,354,762 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document |
| May 05, 2021 Filed May 6, 2021 17:28 UTC | Neurogene Inc. NLTX · Entity 5160 | SaleCommon Stock | 1,200 | $11.30 | $13,560.00 |
DisclosureSEC source: 0001209191-21-030654 · doc4.xml · nonDerivative · entry 1 Walkey Carl · CIK 0001843189 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,355,962 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document |
| April 28, 2021 Filed Apr 30, 2021 17:52 UTC | Neurogene Inc. NLTX · Entity 5160 | SaleCommon Stock | 2,400 | $12.58 | $30,192.00 |
DisclosureSEC source: 0001209191-21-029342 · doc4.xml · nonDerivative · entry 1 Walkey Carl · CIK 0001843189 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,357,162 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $12.44 and the highest price at which shares were sold was $13.00. The reporting person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. Read SEC document |
| April 26, 2021 Filed Apr 27, 2021 19:59 UTC | Neurogene Inc. NLTX · Entity 5160 | SaleCommon Stock | 600 | $13.00 | $7,800.00 |
DisclosureSEC source: 0001209191-21-028727 · doc4.xml · nonDerivative · entry 1 Walkey Carl · CIK 0001843189 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,359,562 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document |
| April 21, 2021 Filed Apr 22, 2021 17:11 UTC | Neurogene Inc. NLTX · Entity 5160 | SaleCommon Stock | 1,800 | $11.98 | $21,564.00 |
DisclosureSEC source: 0001209191-21-027971 · doc4.xml · nonDerivative · entry 1 Walkey Carl · CIK 0001843189 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,360,162 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $11.97 and the highest price at which shares were sold was $12.00. The reporting person undertakes to provide upon request to the staff of the Securities Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. Read SEC document |
| April 14, 2021 Filed Apr 16, 2021 19:08 UTC | Neurogene Inc. NLTX · Entity 5160 | SaleCommon Stock | 1,800 | $12.22 | $21,996.00 |
DisclosureSEC source: 0001209191-21-027050 · doc4.xml · nonDerivative · entry 1 Walkey Carl · CIK 0001843189 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,361,962 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document |
| April 07, 2021 Filed Apr 8, 2021 19:06 UTC | Neurogene Inc. NLTX · Entity 5160 | SaleCommon Stock | 1,800 | $12.02 | $21,636.00 |
DisclosureSEC source: 0001209191-21-026153 · doc4.xml · nonDerivative · entry 1 Walkey Carl · CIK 0001843189 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,363,762 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document |
| April 05, 2021 Filed Apr 6, 2021 20:37 UTC | Neurogene Inc. NLTX · Entity 5160 | SaleCommon Stock | 600 | $13.00 | $7,800.00 |
DisclosureSEC source: 0001209191-21-025767 · doc4.xml · nonDerivative · entry 1 Walkey Carl · CIK 0001843189 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,365,562 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document |
| March 31, 2021 Filed Apr 2, 2021 17:21 UTC | Neurogene Inc. NLTX · Entity 5160 | SaleCommon Stock | 1,800 | $11.96 | $21,528.00 |
DisclosureSEC source: 0001209191-21-024707 · doc4.xml · nonDerivative · entry 1 Walkey Carl · CIK 0001843189 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,366,162 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $11.94 and the highest price at which shares were sold was $12.00. The reporting person undertakes to provide upon request to the staff of the Securities Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. Read SEC document |
| March 24, 2021 Filed Mar 24, 2021 18:48 UTC | Neurogene Inc. NLTX · Entity 5160 | SaleCommon Stock | 1,800 | $11.95 | $21,515.94 |
DisclosureSEC source: 0001209191-21-022929 · doc4.xml · nonDerivative · entry 2 Walkey Carl · CIK 0001843189 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,367,962 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $11.93 and the highest price at which shares were sold was $12.00. The reporting person undertakes to provide upon request to the staff of the Securities Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. Read SEC document |
| March 22, 2021 Filed Mar 24, 2021 18:48 UTC | Neurogene Inc. NLTX · Entity 5160 | SaleCommon Stock | 600 | $12.00 | $7,200.00 |
DisclosureSEC source: 0001209191-21-022929 · doc4.xml · nonDerivative · entry 1 Walkey Carl · CIK 0001843189 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,369,762 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document |
| March 17, 2021 Filed Mar 18, 2021 20:45 UTC | Neurogene Inc. NLTX · Entity 5160 | SaleCommon Stock | 1,200 | $11.36 | $13,632.00 |
DisclosureSEC source: 0001209191-21-021946 · doc4.xml · nonDerivative · entry 1 Walkey Carl · CIK 0001843189 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,370,362 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document |
| March 10, 2021 Filed Mar 11, 2021 16:14 UTC | Neurogene Inc. NLTX · Entity 5160 | SaleCommon Stock | 1,800 | $11.97 | $21,540.06 |
DisclosureSEC source: 0001209191-21-019776 · doc4.xml · nonDerivative · entry 1 Walkey Carl · CIK 0001843189 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,371,562 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $11.95 and the highest price at which shares were sold was $12.00. The reporting person undertakes to provide upon request to the staff of the Securities Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. Read SEC document |
| March 03, 2021 Filed Mar 4, 2021 18:52 UTC | Neurogene Inc. NLTX · Entity 5160 | SaleCommon Stock | 1,800 | $11.87 | $21,360.06 |
DisclosureSEC source: 0001209191-21-017994 · doc4.xml · nonDerivative · entry 1 Walkey Carl · CIK 0001843189 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,373,362 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $11.80 and the highest price at which shares were sold was $12.00. The reporting person undertakes to provide upon request to the staff of the Securities Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. Read SEC document |
| February 25, 2021 Filed Feb 25, 2021 20:17 UTC | Neurogene Inc. NLTX · Entity 5160 | SaleCommon Stock | 600 | $13.00 | $7,800.00 |
DisclosureSEC source: 0001209191-21-014513 · doc4.xml · nonDerivative · entry 2 Walkey Carl · CIK 0001843189 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,375,162 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document |
| February 24, 2021 Filed Feb 25, 2021 20:17 UTC | Neurogene Inc. NLTX · Entity 5160 | SaleCommon Stock | 1,800 | $12.14 | $21,852.00 |
DisclosureSEC source: 0001209191-21-014513 · doc4.xml · nonDerivative · entry 1 Walkey Carl · CIK 0001843189 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,375,762 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document |
| February 17, 2021 Filed Feb 18, 2021 16:20 UTC | Neurogene Inc. NLTX · Entity 5160 | SaleCommon Stock | 2,400 | $12.70 | $30,480.00 |
DisclosureSEC source: 0001209191-21-011834 · doc4.xml · nonDerivative · entry 1 Walkey Carl · CIK 0001843189 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,377,562 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $12.62 and the highest price at which shares were sold was $13.00. The reporting person undertakes to provide upon request to the staff of the Securities Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 16:23 UTC | Neurogene Inc. NLTX · Entity 5160 | SaleCommon Stock | 3,000 | $14.20 | $42,600.00 |
DisclosureSEC source: 0001209191-21-010148 · doc4.xml · nonDerivative · entry 1 Walkey Carl · CIK 0001843189 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,379,962 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document |
| February 05, 2021 Filed Feb 9, 2021 16:41 UTC | Neurogene Inc. NLTX · Entity 5160 | SaleCommon Stock | 600 | $14.00 | $8,400.00 |
DisclosureSEC source: 0001209191-21-008839 · doc4.xml · nonDerivative · entry 1 Walkey Carl · CIK 0001843189 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,382,962 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 16:51 UTC | Neurogene Inc. NLTX · Entity 5160 | SaleCommon Stock | 2,400 | $13.23 | $31,752.00 |
DisclosureSEC source: 0001209191-21-008129 · doc4.xml · nonDerivative · entry 1 Walkey Carl · CIK 0001843189 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,383,562 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document |
| January 30, 2021 Filed Feb 2, 2021 16:11 UTC | Neurogene Inc. NLTX · Entity 5160 | GrantStock Option (Right to Buy) · Derivative | 45,000 | $0.00 Strike: $12.60 | $0.00 |
DisclosureSEC source: 0001209191-21-006730 · doc4.xml · derivative · entry 1 Walkey Carl · CIK 0001843189 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2031-01-30 F1 · derivative.exercise_date: The option vests as to 1/4 of the total shares on January 30, 2022, and then 1/48 of the total shares will vest monthly thereafter, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.